Previous company name
Name change date
Zentiva N.V. is an international pharmaceutical company based in the Netherlands which develops, manufactures and markets modern branded generic pharmaceutical products including pharmaceutical chemicals, cosmetics, packaging materials, and special purpose equipment and machines for the pharmaceutical industry. The company was formed in 2003 by the merger of Lйciva and Slovakofarma, both are pharmaceutical companies in the Czech and Slovak Republics. Its headquarters is located in Amsterdam, the capital city of the Netherlands.
Zentiva is the market leader in the Czech Republic, Romania, and Slovakia, and grows dynamically in Poland, Russia, Bulgaria, Ukraine and the Baltic countries which include Estonia, Latvia and Lithuania. Its largest market is the Czech Republic where it is the leading supplier of prescription and CHC medicines. The company’s product range consists of almost 280 products in some 500 pharmaceutical presentations, covering a wide range of therapeutic area. The company focuses on the treatment of cardiovascular diseases, inflammatory conditions, pain, and infections and disorders of central nervous system and gastrointestinal and urinary tracts. Its key product in food supplements are vitamin preparations.
Zentiva is the largest generic pharmaceutical companies in Central and Eastern Europe. The company’s mission is to develop, produce and sell pharmaceutical products that help improve the quality of human life and extend the scope of high-quality healthcare, especially in the area of primary care. It aims for profitable growth and to increase the availability of modern drugs to patients in Central and Eastern Europe through primary care providers. The company has manufacturing plants located in the Czech Republic, Slovakia and Romania.
The Company is one of the largest generic pharmaceutical companies in Central and Eastern Europe. The Company is primarily engaged in the production, development and sales of generic pharmaceuticals, including pharmaceutical chemicals, cosmetics and packaging materials for pharmaceutical products and special purpose equipment and machines for the pharmaceutical industry.
Description and history
The Company is one of the largest generic pharmaceutical companies in Central and Eastern Europe. The Company focuses on developing, manufacturing and marketing new branded generic versions of modern pharmaceutical products, which the Company believes can be successfully introduced to the primary care markets of Central and Eastern Europe. Currently, the majority of the company’s operations are in the Czech Republic and Slovakia where Zentiva is the leading pharmaceutical company in both markets. The Company is continuing to expand its business with significant growth taking place in both Poland and Russia.
The Company group was formed in August 2003 by the merger of Lйciva and Slovakofarma, the highly prosperous and largest and most highly prosperous pharmaceutical companies in the Czech and Slovak Republics.
On the 11th of August 2003, the Slovak antitrust office gave approval for the Company , the majority shareholder in Lйciva a.s., to take a majority stake in Slovakofarma a.s. On the 18th of August 2003, the acquisition by a new majority shareholder was completed. From the 1st of September the products of both companies began to be sold under the new name Zentiva.
The Company was incorporated as a private limited liability company on 29 April 1998 with its registered seat in Amsterdam, the Netherlands. On 21 May 2004, Zentiva B.V. was converted to Zentiva N.V., a public limited liability company. The Company is the parent company of Zentiva Group.
In 1998 the Company acquired a majority of voting rights in Leciva, a.s. (now Zentiva, a.s. Prague) that was established on 1 April 1993 through a transformation of a state company. Later in 1998, Leciva, a.s. acquired controlling share of VUFB a.s., a company engaged in research and development of pharmaceuticals.
In August 2003 the Company acquired a 100% share of SL Pharma, an Austrian holding company that was a 69 % shareholder of SLOVAKOFARMA a.s. group (now Zentiva, a.s. Hlohovec) and the investment of Zentiva N.V. in Zentiva, a.s. Hlohovec was increased to 85.02% for total consideration of CZK 1,936,877 thousand as of 31 December 2003. In 2004 and 2005 Zentiva N.V. acquired additional 5.73% and 0.8% of Zentiva, a.s.
As at 1 January 2005, Zentiva, a.s. and VUFB, a.s. were merged. During 2005 Zentiva N.V. acquired remaining portion of the freestanding minority interest in Zentiva, a.s. Prague and the investment in Zentiva, a.s. Prague was increased to 100%.
Sicomed Acquisition in 2005
In line with its strategy for profitable growth Zentiva acquired a 51% interest in Sicomed Romania’s largest generics manufacturer via the purchase of Venoma Holdings in October 2005. This acquisition has made Romania become Zentiva’s fifth core market. Following a tender offer, which completed on January 20, 2006
Transfer of Zentiva, a.s. (Hlohovec) shares from SL Pharma to Zentiva N.V.
At the end of June 2006, a 67% stake in Zentiva, a.s. (Hlohovec) was transferred from Zentiva N.V.’s wholly owned Austrian subsidiary, SL Pharma, to Zentiva N.V. As a result, Zentiva N.V. now has more than 90% direct stake in its Slovak subsidiary Zentiva, a.s. (Hlohovec).
Termination of listing of The Company’s global depositary shares on the London Stock Exchange became effective as of April 24, 2009.
The Company has been takeover by Sanofi-Aventis.
Formed by the merger of Lйciva and Slovakofarma
Develops, manufactures and markets modern branded generic pharmaceutical products
ECZACIBAS-ZENTIVA KIMYASAL URUNLER
ERNST & YOUNG AUDIT S.R.O.
US SIC Code
FRED. ROESKESTRAAT 123 1H
City province or state postal code
1076 EE, AMSTERDAM
Phone: +31 20 673 9753
Fax: +31 20 470 8362
Country address: NETHERLANDS
Website url: www.zentiva.nl